Latest news
Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results - MarketBeatMarketBeat · Sat, 08 Aug 2026 03:37:39 GMTGYRE: Net loss widened to $32.8 million on $53.5 million revenue, with strong liquidity maintained - TradingViewTradingView · Fri, 07 Aug 2026 21:03:24 GMTGyre Therapeutics (NASDAQ: GYRE) swings to 32,849 H1 2026 net loss - Stock TitanStock Titan · Fri, 07 Aug 2026 21:01:46 GMTGyre Therapeutics Releases Q2 2026 Financial Results - AlphaStreetAlphaStreet · Fri, 07 Aug 2026 18:05:06 GMTGyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKeyTradingKey · Fri, 07 Aug 2026 17:57:54 GMTH.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - MoomooMoomoo · Fri, 07 Aug 2026 17:25:43 GMTGyre Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 16:36:02 GMTGyre Therapeutics Q2 EPS misses estimate despite sales beat - scanx.tradescanx.trade · Fri, 07 Aug 2026 15:21:49 GMT